market folly

Andreas Halvorsen's hedge fund firm Viking Global has filed a 13G with the SEC regarding shares of Kite Pharma (KITE).  Per the filing, Viking now owns 5% of the company with 2.44 million shares.

This is up from the 2.2 million shares they owned at the end of 2015 and the latest filing was made due to activity on February 18th.

To see the rest of Viking Global's portfolio, head to the brand new issue of our Hedge Fund Wisdom newsletter.

Per Google Finance, Kite Pharma is "a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company's lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.."